Phase II/III Study of Anti-VEGF in Neovascular AMD
Completed · Phase 2/Phase 3
Conditions studied: Macular Degeneration, Choroidal Neovascularization
In brief
The purpose of the study is to determine whether the anti-VEGF drug is effective at stabilizing and/or improving vision in patients with the wet form of AMD
Key facts
- Study ID
- NCT00021736
- Run by
- Eyetech Pharmaceuticals
- People needed
- 540
- Starts
- 2001-07-01
- Expected to finish
- 2002-07-01
- Last updated by the study team
- 2005-06-24
Who can join
Age: 50 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Foundation for Fighting Blindness — Baltimore, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.